#USA #New York #Gross Law Firm #Rocket Pharmaceuticals #RCKT

Class Action Lawsuit Against Rocket Pharmaceuticals, Inc.

On July 21, 2025, The Gross Law Firm announced a class action lawsuit against Rocket Pharmaceuticals, Inc., a public biotechnology company traded as NASDAQ: RCKT. This notification is critical for shareholders who acquired shares between February 27, 2025, and May 26, 2025, as they are encouraged to participate due to alleged misleading statements made by the company's management.

Background of the Allegations

The core of the allegations revolves around claims that Rocket Pharmaceuticals provided investors with overly optimistic projections regarding their clinical drug candidate, RP-A501. During the class period, the company ostensibly failed to disclose material adverse information, particularly about the safety of RP-A501 and the clinical trial protocols, which had significantly evolved.

The lawsuit alleges that shareholders were not made aware that Rocket introduced a new immunomodulatory agent into the pretreatment regimen of the clinical trial. Worse yet, it is asserted that there were significant risks associated with Serious Adverse Events (SAEs), which included the unfortunate instance of a participant’s death during the trial phase. These crucial updates were not communicated to shareholders until after a serious event occurred, raising serious concerns about the company's transparency and ethical management practices.

Financial Impact on Shareholders

Rocket Pharmaceuticals experienced a dramatic financial fallout following the revelation of the serious adverse event and the FDA's decision to impose a clinical hold on the RP-A501 Phase 2 pivotal study. Prior to this news, the stock was valued at $6.27 per share; however, following the announcement on May 27, 2025, regarding the SAEs, the price plummeted by 37%, closing at $2.33 per share just one trading day later. This decline illustrates the severe impact that such disclosures can have on investor confidence and stock valuation.

Call to Action for Investors

The deadline for shareholders to register for potential participation in this class action lawsuit is August 11, 2025. Those who purchased Rocket shares during the specified class period and are interested in holding the company accountable for the alleged deceptive practices should not miss the chance to join the lawsuit. The Gross Law Firm is welcoming inquiries regarding lead plaintiff appointments, though it is not a prerequisite for participating in any recovery.

Investors can register online to stay updated about the developments regarding the case, and to monitor their status as this lawsuit progresses through the legal system. Investing in this case entails no costs or obligations on the shareholders’ end.

Why Choose Gross Law Firm?

The Gross Law Firm is dedicated to ensuring that corporate entities comply with their obligations to shareholders and act with full transparency. With a proven track record in handling class action cases, the firm’s focus remains on restoring equity to those who have suffered financial losses due to misleading or fraudulent disclosures by public companies. Their commitment goes beyond just legal obligations; they strive to advocate for responsible corporate governance and uphold investor rights.

For inquiries or further information, shareholders are encouraged to contact The Gross Law Firm directly. As these matters develop, it is crucial for shareholders to stay informed and actively participate in safeguarding their investment interests.

Contact Information

To get involved or learn more, please reach out to:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

This class action lawsuit represents a vital opportunity for investors to take a stand against corporate misconduct in the biotech sector. With an emphasis on transparency and accountability, shareholders have the chance to collectively seek redress for their losses and hold Rocket Pharmaceuticals accountable for their actions.